The EGFR targeting antibodies bind to the extracellular domain of EGFR, leading to the inhibition of its downstream signaling pathways, including the RAS-RAF-mitogen-activated protein kinase 1 (MAPK1) axis that is mainly involved in cell proliferation, and the v-akt murine thymoma viral oncogene homolog 1 (AKT1) pathway, which is mainly involved in cell survival and tumor invasion [5]. Here, AKT1 is linked to neoplasm.